BOSTON (TheStreet) -- The safest investments are companies that can grow in any economy -- boom or bust. The following five are expected to increase revenue and profit by at least 12% in the coming year.

5. Lincoln Educational Services ( LINC) provides career education.

The numbers: Third-quarter profit more than doubled to $14 million, or 50 cents a share, as revenue grew 48% to $148 million. Lincoln's operating margin stretched from 10% to 16%. The company has an admirable financial position, with $38 million of cash and $37 million of debt.

The stock: Lincoln increased 18% during the past year, less than major U.S. indices. The stock trades at a price-to-earnings ratio of 13, a discount to diversified consumer services peers. Lincoln doesn't pay dividends.

4. Medco Health Solutions ( MHS) is a pharmacy-benefits manager.

The numbers: Third-quarter net income increased 13% to $336 million, and earnings per share climbed 19% to 69 cents, boosted by a lower share count. Revenue grew 18% to $15 billion. Medco's operating margin remained steady at 4%. A quick ratio of 1 and debt-to-equity ratio of 0.7 indicate a sound financial position.

The stock: Medco advanced 27% during the past year, beating the Dow Jones Industrial Average and S&P 500 Index. The stock trades at a price-to-earnings ratio of 24, a premium to health-care-services peers. Medco doesn't pay dividends.

3. Bio-Reference Laboratories ( BRLI) provides clinical-testing services in the New York metropolitan area.

The numbers: Fiscal fourth-quarter profit increased 37% to $7.2 million, or 51 cents a share, as revenue advanced 26% to $102 million. Bio-Reference's operating margin ascended from 12% to 13%. The company is financially sound, evident in its quick ratio of 1.9 and debt-to-equity ratio of 0.2.

The stock: Bio-Reference increased 46% during the past year, outpacing major U.S. indices. The stock trades at a price-to-earnings ratio of 24, a premium to health-care-services peers. Bio-Reference doesn't pay dividends.

2. DeVry ( DV) is a for-profit educator.

The numbers: Fiscal second-quarter profit increased 69% to $72 million, or $1 a share, as revenue grew 28% to $473 million. DeVry's operating margin widened from 17% to 23%. The company has a liquid balance sheet, with $389 million of cash and $45 million of debt.

The stock: DeVry advanced 7% during the past year, lagging behind major U.S. indices. The stock trades at a price-to-earnings ratio of 21, on par with diversified consumer-services peers. The shares offer a 0.3% dividend yield.

1. Teva Pharmaceuticals ( TEVA) is an Israeli drugmaker.

The numbers: Third-quarter net income inched up 3% to $649 million, but earnings per share fell 6% to 72 cents. Revenue increased 25% to $3.6 billion. Teva's operating margin ascended from 23% to 24%. A quick ratio of 0.9 indicates less-than-ideal liquidity. A debt-to-equity ratio of 0.3 reflects modest leverage.

The stock: Teva rose 35% during the past year, beating the Dow and S&P 500. The stock trades at a price-to-earnings ratio of 61, a premium to pharmaceutical peers. The shares offer a 1.1% dividend yield.

Five Value Stocks That Defy Market Decline

More from Investing

Dow Futures Pop Despite Rising Trade War Fears

Dow Futures Pop Despite Rising Trade War Fears

Why GE's Stock Has Fallen 9% in the Last 30 Days

Why GE's Stock Has Fallen 9% in the Last 30 Days

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Worries About a Trade War Could Throw Wrench Into the Tech Stock Rally

Worries About a Trade War Could Throw Wrench Into the Tech Stock Rally

5 Stock Picks Under $10 for Millennials

5 Stock Picks Under $10 for Millennials